<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Inzucchi, Silvio E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Glucose Lowering: New Options</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">35-35</style></pages><abstract><style  face="normal" font="default" size="100%">The most common treatments for diabetes include lifestyle changes (diet and exercise); oral medications, such as the sulfonylureas, biguanides, thiazolidinediones, meglitinides, and alpha-glucosidase inhibitors; and parenteral insulin therapy. This article discusses a new line of therapy using incretins.</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>